Literature DB >> 28475024

Correlations of 18F-FDG and 18F-FLT uptake on PET with Ki-67 expression in patients with lung cancer: a meta-analysis.

Guohua Shen1, Huan Ma2, Fuwen Pang1, Pengwei Ren3, Anren Kuang1.   

Abstract

Background Positron emission tomography (PET) imaging using the radiotracers 18F-fluorodeoxyglucose (FDG) or 18F-fluorothymidine (FLT) has been proposed as imaging biomarkers of cell proliferation. Purpose To explore the correlations of FDG and FLT uptake with the Ki-67 labeling index in patients with lung cancer. Material and Methods Major databases were systematically searched for all relevant literature published in English. The correlation coefficient (rho) and its 95% confidence interval (CI) of individual studies were meta-analyzed using a random-effects model. The sources of heterogeneity were explored by subgroup analyses. Results Twenty-seven articles involving 1213 patients were included in this meta-analysis, comprising 22 studies for FDG uptake/Ki-67 expression correlation and eight for FLT uptake/Ki-67 expression correlation. The pooled rho values for 18F-FDG/Ki-67 correlation and 18F-FLT/Ki-67 correlation were 0.45 (95% CI, 0.41-0.50) and 0.65 (95% CI, 0.56-0.73), respectively, which indicated a moderate correlation for the former and a significant one for the latter. Although the subgroup analyses based on study design, scanner, sample method, and Ki-67 labeling method did not significantly explain the heterogeneity, these factors were potential sources of heterogeneity. In lung cancer, the pooled SUVmax of FDG uptake was significantly higher than that of FLT uptake (7.59 versus 3.86, P < 0.05). In addition, compared to FDG, FLT showed higher specificity yet lower sensitivity for the diagnosis of pulmonary lesions. Conclusion Both 18F-FDG and 18F-FLT correlate significantly with the Ki-67 labeling index in pulmonary lesions, and the latter, with a stronger correlation, may be more reliable for assessing tumor cell proliferation in lung cancer.

Entities:  

Keywords:  Fluorothymidine; Ki-67; fluorodeoxyglucose; lung cancer; meta-analysis

Mesh:

Substances:

Year:  2017        PMID: 28475024     DOI: 10.1177/0284185117706609

Source DB:  PubMed          Journal:  Acta Radiol        ISSN: 0284-1851            Impact factor:   1.990


  13 in total

1.  The role of 18F-FDG PET/CT in diagnosis and treatment evaluation for ocular adnexal mucosa-associated lymphoid tissue lymphoma.

Authors:  Weifang Wang; Xiaochen Ni; Tianci Tang; Jie Wang; Yi Li; Xinmao Song
Journal:  Br J Radiol       Date:  2021-12-17       Impact factor: 3.039

2.  Development and validation of novel radiomics-based nomograms for the prediction of EGFR mutations and Ki-67 proliferation index in non-small cell lung cancer.

Authors:  Yinjun Dong; Zekun Jiang; Chaowei Li; Shuai Dong; Shengdong Zhang; Yunhong Lv; Fenghao Sun; Shuguang Liu
Journal:  Quant Imaging Med Surg       Date:  2022-05

3.  18F-FLT PET/CT Adds Value to 18F-FDG PET/CT for Diagnosing Relapse After Definitive Radiotherapy in Patients with Lung Cancer: Results of a Prospective Clinical Trial.

Authors:  Tine Nøhr Christensen; Seppo W Langer; Gitte Persson; Klaus Richter Larsen; Annika Loft; Annemarie Gjelstrup Amtoft; Anne Kiil Berthelsen; Helle Hjorth Johannesen; Sune Høgild Keller; Andreas Kjaer; Barbara Malene Fischer
Journal:  J Nucl Med       Date:  2020-10-09       Impact factor: 10.057

Review 4.  Molecular imaging of pulmonary diseases.

Authors:  Julien Dimastromatteo; Eric J Charles; Victor E Laubach
Journal:  Respir Res       Date:  2018-01-24

5.  Standardized Uptake Values Derived from 18F-FDG PET May Predict Lung Cancer Microvessel Density and Expression of KI 67, VEGF, and HIF-1α but Not Expression of Cyclin D1, PCNA, EGFR, PD L1, and p53.

Authors:  Alexey Surov; Hans Jonas Meyer; Andreas Wienke
Journal:  Contrast Media Mol Imaging       Date:  2018-06-06       Impact factor: 3.161

6.  Associations Between PET Parameters and Expression of Ki-67 in Breast Cancer.

Authors:  Alexey Surov; Hans Jonas Meyer; Andreas Wienke
Journal:  Transl Oncol       Date:  2018-12-03       Impact factor: 4.243

7.  The thymidine dideoxynucleoside analog, alovudine, inhibits the mitochondrial DNA polymerase γ, impairs oxidative phosphorylation and promotes monocytic differentiation in acute myeloid leukemia.

Authors:  Dana Yehudai; Sanduni U Liyanage; Rose Hurren; Biljana Rizoska; Mark Albertella; Marcela Gronda; Danny V Jeyaraju; Xiaoming Wang; Samir H Barghout; Neil MacLean; Thirushi P Siriwardena; Yulia Jitkova; Paul Targett-Adams; Aaron D Schimmer
Journal:  Haematologica       Date:  2018-12-20       Impact factor: 9.941

8.  Early Response Assessment to Targeted Therapy Using 3'-deoxy-3'[(18)F]-Fluorothymidine (18F-FLT) PET/CT in Lung Cancer.

Authors:  Kalevi Kairemo; Elmer B Santos; Homer A Macapinlac; Vivek Subbiah
Journal:  Diagnostics (Basel)       Date:  2020-01-06

Review 9.  Clinical value of 3'-deoxy-3'-[18F]fluorothymidine-positron emission tomography for diagnosis, staging and assessing therapy response in lung cancer.

Authors:  Sergio Dall'Angelo; Ian N Fleming; Bandar Alwadani
Journal:  Insights Imaging       Date:  2021-07-02

Review 10.  Spatial heterogeneity of nanomedicine investigated by multiscale imaging of the drug, the nanoparticle and the tumour environment.

Authors:  Josanne Sophia de Maar; Alexandros Marios Sofias; Tiffany Porta Siegel; Rob J Vreeken; Chrit Moonen; Clemens Bos; Roel Deckers
Journal:  Theranostics       Date:  2020-01-01       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.